Research Progress of Cholestatic Liver Disease-Related Pruritus in Chinese Medicine and Western Medicine

Abstract

Pruritus is common in cholestatic liver disease, with a high clinical incidence rate and complex pathogenesis. Accumulation of potential pruritus inducers such as steroids, bile acids, and lysophosphatidic acid in the systemic circulation is the main cause of pruritus in cholestatic liver disease. Currently, clinical treatment of cholestatic liver disease-related pruritus mainly includes medication, intervention therapy, and some experimental methods. However, there are still problems, such as unclear pathological mechanisms and unsatisfactory treatment responses in some patients with cholestatic liver disease-related pruritus. Effective treatment for patients still faces challenges. By extensively screening patients' plasma (and/or bile) samples through clinical trials, potential pruritus inducers can be identified comprehensively, which can provide a deeper understanding of the itch signaling pathways in cholestatic liver disease and a basis for the development of treatment strategies. Traditional Chinese medicine (TCM) has shown certain characteristics and advantages in clinical treatment. Based on the etiology and pathogenesis, external application, internal administration, and TCM-specific therapies have achieved good clinical efficacy. Similarly, the combination of Chinese medicine and Western medicine has also achieved more effective treatment for patients with cholestatic liver disease-related pruritus. This article will introduce the latest progress in the study of pruritus inducers in cholestatic liver disease and its treatment in TCM and Western medicine.

Keywords

cholestasis - pruritus - Chinese medicine - Western medicine - research progress

CRediT Authorship Contribution Statement

Wenzhang Dai: Investigation, and writing—original draft. Hong Nie: Funding Acquisition, and writing—review & editing.

Publikationsverlauf

Eingereicht: 02. Februar 2024

Angenommen: 22. März 2024

Artikel online veröffentlicht:
27. Juni 2024

• References

• 1 Lu XL, Xia QY. Progress in pathogenesis and treatment of cholestatic pruritus. J Intern Med Concepts Pract 2022; 17 (01) 43-47
• 2 Beuers U, Kremer AE, Bolier R, Elferink RP. Pruritus in cholestasis: facts and fiction. Hepatology 2014; 60 (01) 399-407
• 3 European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. European association for the study of the liver electronic address: EASLOFFICE@EASLOFFICE EU, EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022; 77 (03) 761-806
• 4 Li SD, Xu CJ, Liu Y. et al. Discussion on the treatment of chronic liver disease patients complicated with skin pruritus. Chin J Integr Tradit West Med Liver Dis 2021; 31 (05) 462-464
• 5 Song XA, Wei ZM, Song M. et al. Recent advances in traditional Chinese and Western medicine diagnosis and treatment of itchy skin secondary to cholestatic liver disease. Infect Dis Inf 2012; 25 (06) 381-384
• 6 Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus: a review. Biochim Biophys Acta Mol Basis Dis 2020; 1866 (12) 165958
• 7 Meixiong J, Dong X. Mas-related G protein-coupled receptors and the biology of itch sensation. Annu Rev Genet 2017; 51: 103-121
• 8 Sanchon-Sanchez P, Herraez E, Macias RIR. et al. Relationship between cholestasis and altered progesterone metabolism in the placenta-maternal liver tandem. Biochim Biophys Acta Mol Basis Dis 2024; 1870 (02) 166926
• 9 Reyes H. Sulfated progesterone metabolites in the pathogenesis of intrahepatic cholestasis of pregnancy: another loop in the ascending spiral of medical knowledge. Hepatology 2016; 63 (04) 1080-1082
• 10 Abu-Hayyeh S, Ovadia C, Lieu T. et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 2016; 63 (04) 1287-1298
• 11 Constantine GD, Simon JA, Pickar JH. et al; REJOICE Study Group. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause 2017; 24 (04) 409-416
• 12 Takanami K, Uta D, Matsuda KI. et al. Estrogens influence female itch sensitivity via the spinal gastrin-releasing peptide receptor neurons. Proc Natl Acad Sci U S A 2021; 118 (31) e2103536118
• 13 Xu S, Cheng Y, Keast JR, Osborne PB. 17beta-estradiol activates estrogen receptor beta-signalling and inhibits transient receptor potential vanilloid receptor 1 activation by capsaicin in adult rat nociceptor neurons. Endocrinology 2008; 149 (11) 5540-5548
• 14 Jin J, Li L, Wang Y. et al. Estrogen alleviates acute and chronic itch in mice. Exp Ther Med 2023; 25 (06) 255
• 15 Yang L, Meng Y, Shi Y, Fang H, Zhang L. Maternal hepatic immunology during pregnancy. Front Immunol 2023; 14: 1220323
• 16 Zhang Y, Hu L, Cui Y. et al. Roles of PPARγ/NF-κB signaling pathway in the pathogenesis of intrahepatic cholestasis of pregnancy. PLoS One 2014; 9 (01) e87343
• 17 Larson SP, Kovilam O, Agrawal DK. Immunological basis in the pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev Clin Immunol 2016; 12 (01) 39-48
• 18 Pataia V, Dixon PH, Williamson C. Pregnancy and bile acid disorders. Am J Physiol Gastrointest Liver Physiol 2017; 313 (01) G1-G6
• 19 Basile F, Santamaria A, Mannucci C. et al. Interleukin 31 is involved in intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med 2017; 30 (09) 1124-1127
• 20 Yu H, Zhao T, Liu S. et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. eLife 2019; 8: e48431
• 21 Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular physiology of bile acid signaling in health, disease, and aging. Physiol Rev 2021; 101 (02) 683-731
• 22 Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11 (01) 55-67
• 23 Alemi F, Kwon E, Poole DP. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 2013; 123 (04) 1513-1530
• 24 Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol 2023; 20 (01) 26-36
• 25 Chen Y, Wang ZL, Yeo M. et al. Epithelia-sensory neuron cross talk underlies cholestatic itch induced by lysophosphatidylcholine. Gastroenterology 2021; 161 (01) 301-317.e16
• 26 Kremer AE, Martens JJ, Kulik W. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139 (03) 1008-1018 , 1018.e1
• 27 Kittaka H, Uchida K, Fukuta N, Tominaga M. Lysophosphatidic acid-induced itch is mediated by signalling of LPA₅ receptor, phospholipase D and TRPA1/TRPV1. J Physiol 2017; 595 (08) 2681-2698
• 28 Düll MM, Kremer AE. Treatment of pruritus secondary to liver disease. Curr Gastroenterol Rep 2019; 21 (09) 48
• 29 Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102 (07) 1528-1536
• 30 Li Y, Tang R, Leung PSC, Gershwin ME, Ma X. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 2017; 16 (09) 885-896
• 31 Hegade VS, Pechlivanis A, McDonald JAK. et al. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver Int 2019; 39 (05) 967-975
• 32 Chen Y, Fang Q, Wang Z. et al. Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke histaminergic itch. J Biol Chem 2016; 291 (19) 10252-10262
• 33 De Vloo C, Nevens F. Cholestatic pruritus : an update. Acta Gastroenterol Belg 2019; 82 (01) 75-82
• 34 Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62 (1, Suppl) S25-S37
• 35 Ovadia C, Sajous J, Seed PT. et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2021; 6 (07) 547-558
• 36 Lens S, Leoz M, Nazal L, Bruguera M, Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014; 34 (02) 197-203
• 37 de Vries E, Bolier R, Goet J. et al; Netherlands Association for the Study of the Liver-Cholestasis Working Group. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology 2021; 160 (03) 734-743.e6
• 38 Geenes V, Chambers J, Khurana R. et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur J Obstet Gynecol Reprod Biol 2015; 189: 59-63
• 39 Kumada H, Miyakawa H, Muramatsu T. et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res 2017; 47 (10) 972-982
• 40 Golpanian RS, Yosipovitch G, Levy C. Use of butorphanol as treatment for cholestatic itch. Dig Dis Sci 2021; 66 (05) 1693-1699
• 41 Mayo MJ, Pockros PJ, Jones D. et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun 2019; 3 (03) 365-381
• 42 Chkheidze R, Joseph R, Burner J, Matevosyan K. Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature. J Clin Apher 2018; 33 (03) 412-418
• 43 Hussain AB, Samuel R, Hegade VS, Jones DE, Reynolds NJ. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy. Br J Dermatol 2019; 181 (06) 1138-1145
• 44 Yang XT. Observation on the therapeutic effect of Chinese medicine in treating acute jaundice type A viral hepatitis through damp heat syndrome differentiation. J Guiyang Univ Tradi Chin Med 2020; 42 (04) 54-58
• 45 Wu WL, Wang J. Clinical study on Qufeng Zhiyang Tang combined with western medicine for liver cirrhosis complicated with jaundice concomitant with pruritus. J New Chin Med 2021; 7 (02) 194-197
• 46 Su C, Feng YX, Hao CH. et al. Clinical study on treatment of jaundiced skin pruritus with ear tip bleeding combined with Qushi Zhiyang formula. Chin Heal Standard Manage 2023; 14 (16) 111-115
• 47 Sun HX. Clinical observation of liver-tonifying and itch-relieving decoction on hepatobiliary pruritus due to liver deficiency and wind generation. Guangming J Chin Med 2017; 32 (19) 2748-2751
• 48 Xia X. Huangqin ointment in the nursing of secondary pruritus of cholestasis liver disease. Chin Med Mod Dist Educ Chin 2016; 14 (12) 123-124
• 49 Liu HX, Yang Q, Wang FF. Clinical effect of fumigation and washing of traditional Chinese medicine in the treatment of skin pruritus secondary to chronic liver disease. Chin Mod Med 2023; 30 (14) 58-61
• 50 Shen C. Clinical observation on the treatment of skin pruritus secondary to chronic cholestatic liver disease by cold compress with traditional Chinese medicine. Chin J Tradit Med Sci Techn 2016; 23 (03) 347-348
• 51 Deng CX. Washing medicine, cupping combined western medicine treatment of chronic cholestatic liver disease pruritus randomized parallel group study. J Tradi Chin Intern Med 2014; 28 (11) 102-104